Xenon Pharmaceuticals Inc. (XENE) — SEC Filings
Xenon Pharmaceuticals Inc. (XENE) — 26 SEC filings. Latest: 8-K (Dec 1, 2025). Includes 10 8-K, 6 10-Q, 4 SC 13G/A.
View Xenon Pharmaceuticals Inc. on SEC EDGAR
Overview
Xenon Pharmaceuticals Inc. (XENE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 1, 2025: Xenon Pharmaceuticals Inc. filed an 8-K on November 24, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits.
Sentiment Summary
Across 26 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 24 neutral. The dominant filing sentiment for Xenon Pharmaceuticals Inc. is neutral.
Filing Type Overview
Xenon Pharmaceuticals Inc. (XENE) has filed 10 8-K, 6 10-Q, 1 8-K/A, 2 DEF 14A, 2 10-K, 4 SC 13G/A, 1 SC 13G with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (26)
Risk Profile
Risk Assessment: Of XENE's 23 recent filings, 2 were flagged as high-risk, 5 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $7,500,000 |
| Net Income | -$240,649,000 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $555,256,000 |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Dr. Ian Mitchell
- Ms. Brenda Wong
- Mr. David M. E. Williams
- Simon Pimstone
- Ian Mortimer
- Abigail P. Johnson
- Massachusetts
- December 29, 2023
- February 8, 2024
Industry Context
The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Xenon Pharmaceuticals rely heavily on innovation and successful clinical trials to bring new therapies to market. The competitive landscape is intense, with many players vying for market share in therapeutic areas. Success often hinges on securing substantial funding to navigate the complex development and approval processes.
Top Tags
financials (6) · pharmaceuticals (5) · corporate-governance (4) · officer-changes (3) · Biotechnology (3) · governance (3) · filing (3) · 10-Q (3) · Xenon Pharmaceuticals (3) · director-changes (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $240.6M | Increased from $168.6M in 2024 for the nine months ended September 30, 2025 |
| Research and Development Expenses | $213.2M | Increased from $150.9M in 2024 for the nine months ended September 30, 2025 |
| Accumulated Deficit | $1,140.1M | As of September 30, 2025, indicating significant historical losses |
| Cash, Cash Equivalents, and Marketable Securities | $555.3M | As of September 30, 2025, down from $754.9M at December 31, 2024 |
| Increase in Net Loss | 42.7% | Year-over-year increase for the nine months ended September 30, 2025 |
| Increase in R&D Expenses | 41.3% | Year-over-year increase for the nine months ended September 30, 2025 |
| Collaboration Revenue | $7.5M | Generated for the nine months ended September 30, 2025, up from $0 in 2024 |
| Common Shares Outstanding | 77,120,168 | As of September 30, 2025 |
| Revenue | $0 | for the three and six months ended June 30, 2025, indicating pre-commercial stage |
| Conformed Period of Report | 2025-06-30 | end date of the reporting period for the 10-Q |
| Filed As Of Date | 2025-08-11 | date the 10-Q was filed with the SEC |
| Reporting Period | Q1 2025 | The period covered by the 10-Q filing. |
| As of Date | 2025-03-31 | The specific date for which financial information is reported. |
| SEC File Number | 001-36687 | Identifies the company's filings with the SEC |
| IRS Employer Identification No. | 98-0661854 | Tax identification number for the company |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant, but non-controlling, stake in Xenon Pharmaceuticals Inc. over the next year.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
- {"claim":"Xenon Pharmaceuticals Inc. stock may see increased institutional interest.","entity":"Xenon Pharmaceuticals Inc.","targetDate":"Q2 2024","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Xenon Pharmaceuticals Inc. (XENE)?
Xenon Pharmaceuticals Inc. has 26 recent SEC filings from Feb 2024 to Dec 2025, including 10 8-K, 6 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of XENE filings?
Across 26 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 24 neutral. The dominant sentiment is neutral.
Where can I find Xenon Pharmaceuticals Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Xenon Pharmaceuticals Inc. (XENE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Xenon Pharmaceuticals Inc.?
Key financial highlights from Xenon Pharmaceuticals Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for XENE?
The investment thesis for XENE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Xenon Pharmaceuticals Inc.?
Key executives identified across Xenon Pharmaceuticals Inc.'s filings include Dr. Ian Mitchell, Ms. Brenda Wong, Mr. David M. E. Williams, Simon Pimstone, Ian Mortimer and 4 others.
What are the main risk factors for Xenon Pharmaceuticals Inc. stock?
Of XENE's 23 assessed filings, 2 were flagged high-risk, 5 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Xenon Pharmaceuticals Inc.?
Recent forward-looking statements from Xenon Pharmaceuticals Inc. include guidance on {"claim":"FMR LLC will maintain a significant, but non-controlling, stake in Xenon Pharmaceuticals Inc. over the next ye and 1 other predictions.